AVASTIN (bevacizumab), monoclonal antibody
ONCOLOGY - Focus
Opinions on drugs - Posted on Oct 12 2016
Reason for request
Re-assessment of the actual benefit and the improvement in actual benefit
In combination with fluoropyrimidine-based chemotherapy, no clinical benefit demonstrated in second-line treatment of metastatic colorectal cancer
- In colorectal cancer, AVASTIN has Marketing Authorisation, in combination with fluoropyrimidine-based chemotherapy, as second-line treatment of metastatic colorectal cancer in adults.
- In a new study, a low gain in overall survival (1.4 months) was observed, and in another study, a lack of gain was observed, with an increase in adverse events in both studies.
- No comparison to an anti-EGFR drug in case of wild-type RAS tumour is available.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments